The investigation of resveratrol and analogs as potential inducers of fetal hemoglobin

Blood Cells, Molecules, and Diseases

Volumn 58, Issue , 2016, Pages 6-12

  Theodorou, Andria ^a,b   Phylactides, Marios ^a   Forti, Luca ^c   Cramarossa, Maria Rita ^c   Spyrou, Pantelis ^a   Gambari, Roberto ^d   Thein, Swee Lay ^b,e   Kleanthous, Marina ^a  

^a CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antioxidant; Beta thalassemia; Fetal hemoglobin; Globin; Resveratrol

Indexed keywords

DECITABINE; HEMOGLOBIN F; RESVERATROL; RESVERATROL DERIVATIVE; UNCLASSIFIED DRUG; ANTIOXIDANT; STILBENE DERIVATIVE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL COUNT; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ERYTHROID PRECURSOR CELL; HUMAN; HUMAN CELL; K562 CELL LINE; NORMAL HUMAN; PRIORITY JOURNAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; K-562 CELL LINE; METABOLISM;

ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; ERYTHROID PRECURSOR CELLS; FETAL HEMOGLOBIN; HUMANS; K562 CELLS; STILBENES;

EID: 84962657806     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2015.11.007     Document Type: Article

References (44)

1. Thein S.L. Beta-thalassemia prototype of a single gene disorder with multiple phenotypes. Int. J. Hematol. 2002, 76(Suppl. 2):96-104.
2. Rochette J., Craig J.E., Thein S.L. Fetal hemoglobin levels in adults. Blood Rev. 1994, 8:213-224.
3. Perrine S.P. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. Pediatr. Ann. 2008, 37:339-346.
4. Ley T.J., Desimone J., Noguchi C.T., Turner P.H., Schechter A.N., Heller P., Nienhuis A.W. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle-cell-anemia. Blood 1983, 62:370-380.
5. Gambari R., Fibach E. Medicinal chemistry of fetal hemoglobin inducers for treatment of beta-thalassemia. Curr. Med. Chem. 2007, 14:199-212.
6. Papanikolaou G., Tzilianos M., Christakis J.I., Bogdanos D., Tsimirika K., MacFarlane J., Goldberg Y.P., Sakellaropoulos N., Ganz T., Nemeth E. Hepcidin in iron overload disorders. Blood 2005, 105:4103-4105.
7. Rund D., Rachmilewitz E. Beta-thalassemia. N. Engl. J. Med. 2005, 353:1135-1146.
8. Fibach E., Rachmilewitz E.A. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia. Ann. N. Y. Acad. Sci. 2010, 1202:10-16.
9. Hershko C., Link G., Cabantchik I. Pathophysiology of iron overload. Ann. N. Y. Acad. Sci. 1998, 850:191-201.
10. Kushner J.P., Porter J.P., Olivieri N.F. Secondary iron overload. Hematol. Am. Soc. Hematol. Educ. Program 2001, 47-61.
11. Tesoriere L., D'Arpa D., Butera D., Allegra M., Renda D., Maggio A., Bongiorno A., Livrea M.A. Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in beta-thalassemia intermedia patients. Free Radic. Res. 2001, 34:529-540.
12. Kalpravidh R.W., Siritanaratkul N., Insain P., Charoensakdi R., Panichkul N., Hatairaktham S., Srichairatanakool S., Phisalaphong C., Rachmilewitz E., Fucharoen S. Improvement in oxidative stress and antioxidant parameters in beta-thalassemia/Hb E patients treated with curcuminoids. Clin. Biochem. 2010, 43:424-429.
13. Prus E., Fibach E. The antioxidant effect of fermented papaya preparation involves iron chelation. J. Biol. Regul. Homeost. Agents 2012, 26:203-210.
14. Siemann E.H., Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic. 1992, 43:49-52.
15. Nakata R., Takahashi S., Inoue H. Recent advances in the study on resveratrol. Biol. Pharm. Bull. 2012, 35:273-279.
16. Birrell M.A., McCluskie K., Wong S., Donnelly L.E., Barnes P.J., Belvisi M.G. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J. 2005, 19:840-841.
17. Schneider Y., Vincent F., Duranton B., Badolo L., Gosse F., Bergmann C., Seiler N., Raul F. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000, 158:85-91.
18. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
19. Berge G., Ovrebo S., Eilertsen E., Haugen A., Mollerup S. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br. J. Cancer 2004, 91:1380-1383.
20. Fremont L., Belguendouz L., Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 1999, 64:2511-2521.
21. Pandey K.B., Rizvi S.I. Protective effect of resveratrol on markers of oxidative stress in human erythrocytes subjected to in vitro oxidative insult. Phytother. Res. 2010, 24(Suppl. 1):S11-S14.
22. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., Wood J.G., Zipkin R.E., Chung P., Kisielewski A., Zhang L.L., Scherer B., Sinclair D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
23. Viswanathan M., Kim S.K., Berdichevsky A., Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 2005, 9:605-615.
24. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., Cellerino A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16:296-300.
25. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 1999, 27:160-169.
26. Hung L.M., Su M.J., Chu W.K., Chiao C.W., Chan W.F., Chen J.K. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br. J. Pharmacol. 2002, 135:1627-1633.
27. Kimura Y., Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131:1844-1849.
28. Elmali N., Baysal O., Harma A., Esenkaya I., Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007, 30:1-6.
29. Tian J., Chen J.W., Gao J.S., Li L., Xie X. Resveratrol inhibits TNF-alpha-induced IL-1beta, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway. Rheumatol. Int. 2013, 33:1829-1835.
30. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
31. Gupta Y.K., Chaudhary G., Srivastava A.K. Protective effect of resveratrol against pentylenetetrazole-induced seizures and its modulation by an adenosinergic system. Pharmacology 2002, 65:170-174.
32. Zhao Y.N., Li W.F., Li F., Zhang Z., Dai Y.D., Xu A.L., Qi C., Gao J.M., Gao J. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem. Biophys. Res. Commun. 2013, 435:597-602.
33. Rodrigue C.M., Arous N., Bachir D., Smith-Ravin J., Romeo P.H., Galacteros F., Garel M.C. Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br. J. Haematol. 2001, 113:500-507.
34. Fibach E., Prus E., Bianchi N., Zuccato C., Breveglieri G., Salvatori F., Finotti A., Lipucci di Paola M., Brognara E., Lampronti I., Borgatti M., Gambari R. Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and beta-thalassemia patients. Int. J. Mol. Med. 2012, 29:974-982.
35. Ponzoni C., Beneventi E., Cramarossa M.R., Raimondi S., Trevisi G., Pagnoni U.M., Riva S., Forti L. Laccase-catalyzed dimerization of hydroxystilbenes. Adv. Synth. Catal. 2007, 349:1497-1506.
36. Fibach E. Techniques for studying stimulation of fetal hemoglobin production in human erythroid cultures. Hemoglobin 1998, 22:445-458.
37. Ou C.N., Rognerud C.L. Rapid analysis of hemoglobin variants by cation-exchange HPLC. Clin. Chem. 1993, 39:820-824.
38. Rutherford T., Clegg J.B., Higgs D.R., Jones R.W., Thompson J., Weatherall D.J. Embryonic erythroid differentiation in the human leukemic cell line K562. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:348-352.
39. Erard F., Dean A., Schechter A.N. Inhibitors of cell division reversibly modify hemoglobin concentration in human erythroleukemia K562 cells. Blood 1981, 58:1236-1239.
40. Moutouh-de Parseval L.A., Verhelle D., Glezer E., Jensen-Pergakes K., Ferguson G.D., Corral L.G., Morris C.L., Muller G., Brady H., Chan K. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J. Clin. Invest. 2008, 118:248-258.
41. Liu B.Q., Gao Y.Y., Niu X.F., Xie J.S., Meng X., Guan Y., Wang H.Q. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochem. Biophys. Res. Commun. 2010, 391:778-782.
42. Franco S.S., De Falco L., Ghaffari S., Brugnara C., Sinclair D.A., Matte A., Iolascon A., Mohandas N., Bertoldi M., An X., Siciliano A., Rimmele P., Cappellini M.D., Michan S., Zoratti E., Anne J., De Franceschi L. Resveratrol accelerates erythroid maturation by activation of FoxO3 and ameliorates anemia in beta-thalassemic mice. Haematologica 2014, 99:267-275.
43. Lancon A., Delmas D., Osman H., Thenot J.P., Jannin B., Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem. Biophys. Res. Commun. 2004, 316:1132-1137.
44. DeSimone J., Koshy M., Dorn L., Lavelle D., Bressler L., Molokie R., Talischy N. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002, 99:3905-3908.